TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-07-06 am EDT
3862.00 JPY   +0.63%
07/01Takeda's Takhzyro Shows 94.8% Reduction in Hereditary Angioedema Attacks in Phase 3 Trial in Children
MT
06/30TAKEDA PHARMACEUTICAL : Phase 3 SPRING study data presented at EAACI
PU
06/30Takeda's TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 Technical AnalysisHistorical ChartNews ChartSector ChartComparison ChartReversed ChartRelative Strength Chart
Static chartExpert dynamic chartDynamic Chart 
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBullishBullish
Resistance3 9304 1694 191
Spread/Res.-1,7%-7,4%-7,9%
Spread/Supp.5,4%9,3%12%
Support3 6653 5353 434
Notations Surperformance© of Takeda Pharmaceutical Company Limited  Help  
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes